FREDUN PHARMACEUTICALS
|
FREDUN PHARMACEUTICALS Last 5 Year Financial Ratios History
[Consolidated]
| Mar2026 | Mar2025 | |
|---|---|---|
| Operational & Financial Ratios | ||
| Earnings Per Share (Rs) | 59.61 | 41.80 |
| CEPS(Rs) | 74.68 | 52.48 |
| DPS(Rs) | 0.70 | 0.70 |
| Book NAV/Share(Rs) | 482.77 | 299.43 |
| Tax Rate(%) | 30.59 | 28.20 |
| Margin Ratios | ||
| Core EBITDA Margin(%) | 14.31 | 11.56 |
| EBIT Margin(%) | 13.58 | 10.99 |
| Pre Tax Margin(%) | 7.40 | 6.06 |
| PAT Margin (%) | 5.13 | 4.35 |
| Cash Profit Margin (%) | 6.43 | 5.46 |
| Performance Ratios | ||
| ROA(%) | 5.78 | 4.05 |
| ROE(%) | 16.09 | 13.96 |
| ROCE(%) | 21.34 | 16.16 |
| Asset Turnover(x) | 1.13 | 0.93 |
| Sales/Fixed Asset(x) | 5.71 | 6.09 |
| Working Capital/Sales(x) | 3.16 | 4.58 |
| Efficiency Ratios | ||
| Fixed Capital/Sales(x) | 0.18 | 0.16 |
| Receivable days | 77.49 | 142.46 |
| Inventory Days | 146.38 | 192.94 |
| Payable days | 93.37 | 160.10 |
| Valuation Parameters | ||
| PER(x) | 28.05 | 15.99 |
| PCE(x) | 22.39 | 12.74 |
| Price/Book(x) | 3.46 | 2.23 |
| Yield(%) | 0.04 | 0.10 |
| EV/Net Sales(x) | 1.69 | 1.05 |
| EV/Core EBITDA(x) | 11.34 | 8.70 |
| EV/EBIT(x) | 12.42 | 9.58 |
| EV/CE(x) | 2.14 | 1.55 |
| M Cap / Sales | 1.44 | 0.70 |
| Growth Ratio | ||
| Net Sales Growth(%) | 40.03 | - |
| Core EBITDA Growth(%) | 72.22 | - |
| EBIT Growth(%) | 73.08 | - |
| PAT Growth(%) | 65.26 | - |
| EPS Growth(%) | 42.59 | - |
| Financial Stability Ratios | ||
| Total Debt/Equity(x) | 0.84 | 1.18 |
| Current Ratio(x) | 1.68 | 1.30 |
| Quick Ratio(x) | 0.77 | 0.57 |
| Interest Cover(x) | 2.20 | 2.23 |
| Total Debt/Mcap(x) | 0.24 | 0.53 |
Compare Financial Ratios of peers of FREDUN PHARMACEUTICALS
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| FREDUN PHARMACEUTICALS | ₹2,471.0 Cr | 1.8% | 65.7% | 311.4% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹456,114.0 Cr | NA | -3.9% | 17.3% | Stock Analytics | |
| DIVIS LABORATORIES | ₹239,321.0 Cr | 5% | 21.5% | 44.5% | Stock Analytics | |
| TORRENT PHARMACEUTICALS | ₹185,924.0 Cr | -2.1% | -0.2% | 34.3% | Stock Analytics | |
| CIPLA | ₹113,778.0 Cr | -2% | -2.5% | -8.1% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹99,025.9 Cr | 0.4% | 4.5% | -4.4% | Stock Analytics | |
FREDUN PHARMACEUTICALS Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| FREDUN PHARMACEUTICALS | 1.8% |
65.7% |
311.4% |
| SENSEX | 0.7% |
0.8% |
-5.1% |
You may also like the below Video Courses
